Loading…
← CockpitCompetitor Analysis › INO Inovio Pharmaceuticals, Inc.Open in the cockpit ↗

Inovio Pharmaceuticals, Inc.INOCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum leader 98
Mkt cap
$317M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$41.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.4%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$1.69
1D+3.7%
1W+14.6%
1M+67.3%
3M+39.7%
6M+37.4%
YTD-2.9%
1Y-14.7%
ATR %13.2%
Beta0.41
52w lowhigh37.9% off high

What Inovio Pharmaceuticals does

Employees: 112

Inovio Pharmaceuticals at a glance

Size Inovio Pharmaceuticals (INO) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $317M, the 3032nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.69 on 18 Nov 2026.

Performance Over six months the shares gained 37.4%, against -22.1% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 63.9% over the last twelve months (peer median +2.5%); the operating margin is -25,953.8% (peer median 3.7%).

Valuation It trades at 921.6× enterprise value to sales against a peer median of 3.3× (most expensive of 19).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026INO 127Peer median 77
Six months, rebased to 100: Inovio Pharmaceuticals against the median of its 20 peers (local-currency closes).

Inovio Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$298,901$65,343$217,756$832,010$10.3M
Revenue growth—-70%-74%-92%—
Gross profit-$2.75M-$2.92M-$2.91M-$2.67M$4.77M
EBITDA-$74.5M-$83.8M-$111M-$132M-$269M
Net income-$71.1M-$84.9M-$107M-$135M-$280M
Free cash flow-$74.4M-$88.9M-$105M-$125M-$217M
Capital expenditure$127,444$285,698$487,832$320,898$969,153
Total debt$7.28M$9.37M$11.9M$30.2M$32.1M

Quarterly statements and history in the cockpit →

Inovio Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%0%+25%+50%368AINDSWFTLABAVIR000790005250ALEMBICLTD301331600538002168RLMD1720MYXSOLARA300086INO6-month return →1-month return →
Up and to the right = strong over both horizons. Inovio Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×500×368AINDSWFTLAB0007900052506883021875INORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Inovio Pharmaceuticals is the large dot.

Inovio Pharmaceuticals competitors and peer comparison

How Inovio Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Inovio Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureINOPeer medianRank in peer set
1-month return+67.3%-8.5%2nd highest of 21
6-month return+37.4%-22.1%3rd highest of 21
Distance from 52-week high-37.9%-37.7%11th highest of 21
Revenue growth (TTM)+63.9%+2.5%3rd highest of 19
Operating margin-25,953.8%3.7%lowest of 19
EV / Sales921.6×3.3×most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%921.6×n/an/a
Kitazato 368A.TJapan$317M+7%+9%52%3.1×-16.8%+5.4%
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%3.4×n/an/a
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%5.6×27.5%-6.4%
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%1.1×n/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%1.8×6.1%+62.1%
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%21.4×n/an/a
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%13.0×44.3%+26.7%
Enwei Pharmaceutical 301331.SZChina$308M-20%-7%5%2.1×14.0%+7.3%
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%6.2×n/an/a
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%7.4×14.3%-14.0%
Hinova Pharmaceuticals 688302.SSChina$305M-35%+251%-195%17.1×n/an/a
Relmada Therapeutics RLMDUnited States$305M-60%n/an/an/an/an/a
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%1.8×-11.5%+10.3%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%1.4×9.2%+6.5%
Mayne Pharma MYX.AXAustralia$333M+155%-6%-14%1.2×19.0%-0.9%
BioDlink International 1875.HKHong Kong$334M-24%-51%-31%4.8×n/an/a
Solara Active Pharma Sciences SOLARA.NSIndia$334M+12%+27%8%2.4×38.3%-3.2%
Honz Pharmaceutical 300086.SZChina$299M-40%-23%-54%7.3×56.0%-12.8%
Zhejiang Shengda Bio-Pharm 603079.SSChina$297M-30%-3%7%2.3×4.6%-0.3%

Questions

Which companies are Inovio Pharmaceuticals's closest peers?
The cockpit's peer set: Kitazato (368A.T), Ind-Swift Laboratories (INDSWFTLAB.NS), Atea Pharmaceuticals (AVIR), Chengdu Huasun Technology (000790.SZ), GC Corp. (005250.KS), Swedencare (SECARE.ST), Foresee Pharmaceuticals (6576.TWO), Alembic (ALEMBICLTD.NS).
Is Inovio Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 921.6× against a peer median of 3.3×, most expensive of 19 in its peer set.
How has Inovio Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +37.4% against -22.1% for the median peer; over one year -14.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.